Expressing support for the designation of November as "Complex Regional Pain Syndrome and Reflex Sympathetic Dystrophy Syndrome Awareness Month".

Bill Number

H.Res. 903

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Health

Status

Introduced

Latest Action

2025-11-20: Referred to the House Committee on Energy and Commerce.

Last Updated

2025-11-25T14:03:00Z

AI-Generated Summary

Purpose

This resolution (H. Res. 903) aims to express the House of Representatives' support for designating November as "Complex Regional Pain Syndrome and Reflex Sympathetic Dystrophy Syndrome Awareness Month." It highlights the challenges of these conditions and emphasizes the need for greater public awareness, better diagnosis, research, and treatment development for this rare neuro-inflammatory disorder, which causes intense chronic pain and can lead to disability.

Key Provisions

• Support for Awareness Month: The House formally supports recognizing November as Awareness Month to provide hope, education, and information to patients, caregivers, and families.
• Recognition of Importance: The resolution underscores the value of:
• Improving public awareness of Complex Regional Pain Syndrome (CRPS), also known as Reflex Sympathetic Dystrophy Syndrome (RSD).
• Promoting accurate and early diagnosis, as the condition is often obscure and lacks a single diagnostic test or cure.
• Advancing research and developing new treatments, diagnostics, and cures, noting the absence of FDA-approved treatments.
• Identifying regulatory pathways for drug development, especially for ultra-rare diseases like CRPS/RSD, building on tools like the FDA's Accelerated Approval Pathway and Patient-Focused Drug Development program.
• Background on the Condition: It describes CRPS/RSD as a rare syndrome triggered by trauma, injury, infection, or surgery, more common in women (especially postmenopausal) and older adults, with low global incidence rates (5–29 per 100,000 people). Patients face diagnosis delays, limited treatment options, and the need for multidisciplinary care.

Significant Changes to Existing Law

This is a non-binding resolution, not a law that amends statutes. It introduces no changes to existing legal frameworks but references supportive measures like the Orphan Drug Act (which aids rare disease research) and the FDA's 1992 Accelerated Approval Pathway (codified by Congress in 2012), which expedites approvals for drugs addressing unmet needs in serious conditions.

Potential Impacts

• On Citizens: Increases visibility for CRPS/RSD, potentially leading to earlier diagnoses, better access to specialized care, and more support for the estimated low-incidence population (higher in women and older adults). It may encourage patients and families to seek multidisciplinary treatment and reduce isolation by fostering community awareness.
• On Government Agencies: Indirectly supports the FDA's role in rare disease drug development by affirming the need for patient perspectives and regulatory innovation, but imposes no new mandates or funding requirements.
• On International Relations: Minimal impact, as the resolution is U.S.-focused, though it notes global incidence rates and could align with broader international efforts on rare diseases.
• Overall: Symbolic boost to advocacy, potentially spurring private research funding and nonprofit efforts without direct enforcement.

Main Stakeholders Affected

• Patients and Families: Primary beneficiaries, as those with CRPS/RSD (a condition affecting multiple body systems and often leading to disability) gain from heightened awareness and calls for better treatments.
• Caregivers and Advocacy Groups: Organizations like the Reflex Sympathetic Dystrophy Syndrome Association (founded in 1984) are highlighted for providing support, education, and research advocacy.
• Medical Professionals and Researchers: Encourages specialists across fields (e.g., neurology, pain management) to improve diagnosis and treatment; benefits from references to FDA pathways and the Orphan Drug Act.
• Government and Regulators: The FDA is indirectly involved through mentions of its programs, but faces no new obligations.

Notable Legal, Constitutional, or Political Implications

• Legal: As a simple house resolution, it has no binding force and requires no presidential approval; it simply expresses congressional sentiment without creating enforceable rights or obligations.
• Constitutional: Aligns with Congress's broad authority to recognize awareness months and promote public health education under its general welfare powers; no conflicts with free speech, privacy, or other rights.
• Political: Demonstrates bipartisan support (introduced by Rep. Tonko and Rep. Miller-Meeks) for rare disease issues, potentially influencing future appropriations for health research or FDA initiatives. It reinforces the role of patient voices in policy without partisan controversy, focusing on a non-controversial health awareness topic.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Tonko, Paul [D-NY-20]

Cosponsors (1)

Rep. Miller-Meeks, Mariannette [R-IA-1]

Recent Actions

• 2025-11-20: Referred to the House Committee on Energy and Commerce.
• 2025-11-20: Submitted in House
• 2025-11-20: Submitted in House

Bill Versions

• Expressing support for the designation of November as "Complex Regional Pain Syndrome and Reflex Sympathetic Dystrophy Syndrome Awareness Month". — issued 2025-11-20 — PDF (4 pages)